Abstract:The Medicines and Healthcare Products Regulatory Agency (MHRA) moves to recommend, for the first time, that a systemic antibiotic (trimethoprim) should have its licence reclassified from prescription ...The Medicines and Healthcare Products Regulatory Agency (MHRA) moves to recommend, for the first time, that a systemic antibiotic (trimethoprim) should have its licence reclassified from prescription only medicine (POM) to pharmacy (P) availability.1 For systemic antibiotics particular concerns exist that do not apply to other medicines.
The use of antibiotics may have an adverse effect not only on the specific patient but also on the public health of the community. Quantifying the relation between antibiotic exposure and resistance …Read More